- Home
- FFA vs DCTH Comparison
FFA vs DCTH Comparison
Compare FFA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- DCTH
- Stock Information
- Founded
- FFA 2004
- DCTH 1988
- Country
- FFA United States
- DCTH United States
- Employees
- FFA N/A
- DCTH N/A
- Industry
- FFA Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- FFA Finance
- DCTH Health Care
- Exchange
- FFA Nasdaq
- DCTH Nasdaq
- Market Cap
- FFA 411.2M
- DCTH 398.2M
- IPO Year
- FFA N/A
- DCTH N/A
- Fundamental
- Price
- FFA $20.85
- DCTH $14.31
- Analyst Decision
- FFA
- DCTH Strong Buy
- Analyst Count
- FFA 0
- DCTH 4
- Target Price
- FFA N/A
- DCTH $22.25
- AVG Volume (30 Days)
- FFA 26.1K
- DCTH 411.6K
- Earning Date
- FFA 01-01-0001
- DCTH 11-08-2024
- Dividend Yield
- FFA 6.72%
- DCTH N/A
- EPS Growth
- FFA N/A
- DCTH N/A
- EPS
- FFA N/A
- DCTH N/A
- Revenue
- FFA N/A
- DCTH $22,644,000.00
- Revenue This Year
- FFA N/A
- DCTH $1,605.13
- Revenue Next Year
- FFA N/A
- DCTH $111.67
- P/E Ratio
- FFA N/A
- DCTH N/A
- Revenue Growth
- FFA N/A
- DCTH 945.91
- 52 Week Low
- FFA $15.84
- DCTH $3.70
- 52 Week High
- FFA $19.30
- DCTH $14.47
- Technical
- Relative Strength Index (RSI)
- FFA 57.47
- DCTH 70.27
- Support Level
- FFA $20.03
- DCTH $12.14
- Resistance Level
- FFA $20.63
- DCTH $12.98
- Average True Range (ATR)
- FFA 0.29
- DCTH 0.77
- MACD
- FFA 0.03
- DCTH 0.16
- Stochastic Oscillator
- FFA 92.13
- DCTH 95.12
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.